Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AAM Urges Congress To Re-evaluate Blocking Act

Report Claims Legislation Could Cost $1.7bn For Each Generic Delayed

Executive Summary

Pointing out the “critical shortcomings of the Blocking Act” in a new report, the AAM has urged the US Congress to re-evaluate the legislation.

You may also be interested in...



Generic Association’s New CEO Signals Focus On Communications

Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.

Generic Association’s New CEO Signals Focus On Communications

Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.

Trump’s US price policy aims to remove barriers

Ending the “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies”, advancing biosimilars and generics to encourage greater competition and offering free generics to low-income seniors are among the measures set out in a “blueprint to lower drug prices” that has just been announced by US President Donald Trump. Billing the reform as “the most sweeping action in history to lower the price of prescription drugs for the American people”, Trump said his administration would be “eliminating the middlemen” and targeting ‘freeloading’ other countries.

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel